Q2 2026 saw net sales rise 13.8% to $872.3M and adjusted EPS jump 28.8% to $2.37, driven by strong growth in high-value biologics and GLP-1 products. Guidance for 2026 projects 10–11% organic revenue growth and adjusted EPS of $8.85–$9.05.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.